Search clinical trials for: Severe Eczema

Total 9861 results

AbbVie

Not yet recruiting

An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China (REACH-AD)

Atopic Dermatitis
Sanofi

Recruiting

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

Dermatitis Atopic

United States
Oneness Biotech Co., Ltd.

Not yet recruiting

Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
AbbVie

Not yet recruiting

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis (Sleep Up)

Sleep Disturbance | Atopic Dermatitis
AbbVie

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic Dermatitis

United States
Akeso

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Corvus Pharmaceuticals, Inc.

Recruiting

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Atopic Dermatitis

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic
Societa Italiana di Dermatologia Medica, Chirurgica...

Recruiting

National Register of Moderate and Severe Adult Atopic Dermatitis (ATOPYREG)

Atopic Dermatitis

Italy
LEO Pharma

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (TRAPEDS 2)

Atopic Dermatitis
Innovaderm Research Inc.

Not yet recruiting

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Chronic Hand Eczema

Canada
Eli Lilly and Company

Not yet recruiting

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China, Korea, Republic of
Lynk Pharmaceuticals Co., Ltd

Recruiting

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

China
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
medac GmbH

Not yet recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Moderate to Severe Atopic Dermatitis
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States, Canada
Sanofi

Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment (AD-BEASCUITS)

Dermatitis Atopic

Italy
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

Dermatitis Atopic

Japan, China, Spain, United States, Argentina, United Kingdom, Denmark, Sweden, Turkey
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

China
Keymed Biosciences Co.Ltd

Not yet recruiting

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Atopic Dermatitis
Guangzhou JOYO Pharma Co., Ltd
Chengdu JOYO pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Nektar Therapeutics

Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Moderate to Severe Atopic Dermatitis

United States, Australia, Canada
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, Canada, Korea, Republic of, Taiwan, China
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Sanofi
Regeneron Pharmaceuticals

Recruiting

Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis (CANDID)

Moderate to Severe Atopic Dermatitis

Canada
Akeso

Not yet recruiting

A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Sanofi
Kymera Therapeutics, Inc.

Recruiting

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (ADVANTA)

Atopic Dermatitis

Greece, Poland, United States, Germany
Brexogen Inc.

Recruiting

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Brexogen Inc.

Not yet recruiting

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
LEO Pharma

Recruiting

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

Chronic Hand Eczema

China
GlaxoSmithKline

Recruiting

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

Dermatitis, Atopic

Canada, Spain, China, United States, Argentina, Poland, Korea, Republic of, Panama, Japan, Bulgaria, Czechia, France, Germany, Greece, Italy, Mexico, Thailand
Jiangsu vcare pharmaceutical technology co., LTD

Recruiting

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Societa Italiana di Dermatologia Medica, Chirurgica...

Recruiting

Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA) (ERUDA)

Atopic Dermatitis

Italy
Almirall, S.A.

Recruiting

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis (ADhope)

Eczema | Atopic Dermatitis

Germany, Netherlands, United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Mazandaran University of Medical Sciences

Recruiting

Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Iran, Islamic Republic of
LEO Pharma

Recruiting

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

Atopic Dermatitis | Atopic Hand Eczema

United States, Canada, United Kingdom, Korea, Republic of
AnaptysBio, Inc.

Recruiting

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Atopic Dermatitis Eczema

Georgia, United States, Australia, Canada, Czechia, New Zealand, Poland
LEO Pharma

Recruiting

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, France, Germany, Japan, Poland, United Kingdom, Czechia, Spain, Romania, Hungary
Eli Lilly and Company

Recruiting

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Taiwan, China, Canada, United States, Hungary, Mexico, Poland, Japan, Korea, Republic of
Amgen

Recruiting

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

Atopic Dermatitis

United States, Japan, Korea, Republic of, Australia, Taiwan, Spain, Switzerland, Germany, Austria, Denmark, China, Netherlands, Hungary, Czechia, Poland, Brazil, France, Greece, Portugal, Italy, Finland, Argentina, Bulgaria, Slovenia, E... and more
Numab Therapeutics AG
Kaken Pharmaceutical Co., Ltd.

Recruiting

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Atopic Dermatitis

Germany, Canada, United States, Poland
Swiss Society of Dermatology and Venereology

Recruiting

Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland

Atopic Dermatitis

Switzerland
Sanofi

Recruiting

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

Dermatitis Atopic

Italy, United Kingdom, Argentina, France, Chile, Czechia, Germany, Japan, Spain, China, Netherlands, Brazil, Canada, Denmark, Korea, Republic of, South Africa, Taiwan, Poland, India, Mexico
Cosmetique Active International

Recruiting

Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis

Skin Diseases | Atopic Dermatitis

Croatia, Germany, Portugal, South Africa, Taiwan, Thailand, Vietnam
Eli Lilly and Company

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)

Eczema | Atopic Dermatitis

United States, Taiwan, Spain, Mexico, Czechia, Brazil, Japan, Australia, Canada, France, Germany, Argentina, Poland
Keymed Biosciences Co.Ltd

Recruiting

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

China
Amgen

Recruiting

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Atopic Dermatitis

United States, Korea, Republic of, Taiwan, Spain, Croatia, China, Greece, Belgium, Thailand, Puerto Rico, Hungary, Poland, Germany, Brazil, Italy, Japan, Canada, France, Romania, Chile

3

Subscribe